Meeting
2024 ASCO Genitourinary Cancers Symposium
Evolving metastatic renal cell carcinoma (mRCC) treatment landscape in the post vascular endothelial growth factor (VEGF) and immune checkpoint inhibitor (IO) setting.
Authors
Neil J. Shah
Memorial Sloan Kettering Cancer Center, New York, NY
Neil J. Shah , Rituparna Bhattacharya , Ning Ning , Reshma Shinde , Jordana Schmier , Malinda Tan , Traci LeMasters , Murali Sundaram , Rodolfo F. Perini , Robert J. Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 406)
DOI
10.1200/JCO.2024.42.4_suppl.406
Abstract #
406
Poster Bd #
G9
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
First Author: Shaan Dudani
Poster
2023 ASCO Annual Meeting
Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens.
First Author: Marc Eid
Poster
2023 ASCO Genitourinary Cancers Symposium
Multi-centre review of systemic anti-cancer prescribing patterns and treatment drop off rates in the United Kingdom 2018-2021.
First Author: John McGrane
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman